Jacob J. Adashek, DO University of South Florida, H. Lee Moffitt Cancer Center and Research Institute discusses AARC 2021 Abstract - Pan-cancer Efficacy Of BRAF and/or MEK Inhibitors In BRAF V600-mutant Multiple Non-melanoma Cancers: A Clinico-genomic Study.
• BRAF and MEK inhibitors have been approved by the FDA for melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. • The lack of clinical value issue-agnostic BRAF inhibition in RAF V600+ colorectal cancer (CRC) has stopped its success as an issue-agnostic treatment.
•The BRAF pathway inhibition is involved in over 20 different cancer forms, according to the Vemurafenib-Basket report and the NCI-match trial.
Patients and Procedures
96,324 samples from 89,754 patients were examined for the prevalence of BRAF mutations and copy number alterations in various cancer forms using the AACR Project Genie database version 8 (accessed July 21, 2020).
• A literature search was performed (using PubMed from 2012 to 2019) for case studies of therapeutic reaction and outcomes in patients with BRA V600 mutation-positive non-melanoma cancers treated with BRAF inhibitors.
• A total of 178 cases were found in the literature, spanning 69 different tumor groups.
Erdheim-Chester cancer (n = 30, 16.9%), papillary thyroid carcinoma (n=16, 8.9%), anaplastic thyroid carcinoma (n = 13, 7.3 percent), and hairy cell leukemia (n = 13, 7.3 percent) were the most frequent instances.
• BRAF V600 mutations, which are found in a variety of non-melanoma cancers, cause oncogene addiction and can be treated clinically in a variety of non-melanoma cancers.
• Drug discovery outside the existing BRAF +/- MEK licensed cancers is needed.